m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0186)
Name
MLN8237
Synonyms
Alisertib
    Click to Show/Hide
Structure
3D MOL
2D MOL
Formula
C27H20ClFN4O4
InChI
1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
InChIKey
ZLHFILGSQDJULK-UHFFFAOYSA-N
PubChem CID
24771867
TTD Drug ID
D0S4JK
DrugBank ID
DB05220
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
In total 1 item(s) under this drug
Crosstalk ID: M6ACROT05726
 Crosstalk Info 
m6A Regulator Methyltransferase-like 16 (METTL16)
 Regulator Info 
m6A Target Transcript inducer of AURKA lysosomal degradation (TIALD)
 Target Gene 
Epigenetic Regulator Transcript inducer of AURKA lysosomal degradation (TIALD)
Regulated Target Aurora kinase A (AURKA)
Crosstalk relationship m6A → ncRNA
Disease Liver cancer
 Disease Info 
References
Ref 1 A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9. doi: 10.1002/art.34330. Epub 2011 Dec 6.